KELUN PHARMA(SZ:002422) Xin Lang Cai Jing·2025-09-23 02:41Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, and was established on May 29, 2002. The company was listed on June 3, 2010. Its main business involves the development, production, and sales of large-volume infusion products. The revenue composition is as follows: non-infusion products 48.37%, infusion products 41.28%, R&D projects 7.01%, and others 3.33% [1]. Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to the parent company was 1.001 billion yuan, down 44.41% year-on-year [2]. - Since its A-share listing, Kelun Pharmaceutical has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed in the last three years [3]. Stock Market Activity - As of September 23, Kelun Pharmaceutical's stock price was 36.54 yuan per share, with a market capitalization of 58.393 billion yuan. The stock has increased by 24.16% year-to-date, but has seen a decline of 0.90% over the last five trading days and 4.35% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 30, where it recorded a net purchase of 31.8792 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Kelun Pharmaceutical was 34,200, an increase of 2.55% from the previous period. The average circulating shares per person were 38,138, a decrease of 2.49% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and a decrease in holdings by Hong Kong Central Clearing Limited [3].